Comparing pneumonia risk in COPD patients initiating Fixed Dose Combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone

David Price, William Henley, Victoria Carter, Derek Skinner, Rebecca Vella, Alberto Papi, Leonardo M Fabbri, Huib AM Kerstjens, Nicolas Roche, Dave Singh, Claus F Vogelmeier, Elif Şen, José Eduardo Delfini Cançado, Elena Nudo, Sara Barile, George Georges

Research output: Contribution to conferenceAbstractpeer-review

Abstract

Background: Randomised Controlled Trials show COPD patients have an increased risk of developing pneumonia when prescribed inhaled corticosteroids (ICS), with both aerosol extrafine particle size and ICS-subtype as potential effect modifiers
Original languageEnglish
Publication statusAccepted/In press - 29 Jul 2021
EventERS International Congress 2021 - Virtual event
Duration: 5 Sept 20218 Sept 2021
https://www.ersnet.org/congress-and-events/congress/

Conference

ConferenceERS International Congress 2021
Abbreviated titleERS
Period5/09/218/09/21
Internet address

Fingerprint

Dive into the research topics of 'Comparing pneumonia risk in COPD patients initiating Fixed Dose Combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone'. Together they form a unique fingerprint.

Cite this